Press Releases

The Burrill Report: An Interview With Anthony Giovinazzo, President and CEO, Cynapsus Therapeutics

April 5, 2022

Cynapsus Therapeutics is a small Canadian specialty pharma trying to reinvent itself. Under Anthony Giovinazzo, who took the helm at the end of 2009, the company has a new name and new focus. It’s hoping that its reformulation of an existing treatment for Parkinson’s disease can put it on a fast path to revenue with limited investment. We spoke to Giovinazzo about the company’s strategy, the advantages of its reformulated version of the long-standing drug apomorphine, and what lessons can be drawn from the company’s approach.

Link to Podast (Audio):

Link to Page:

Horizonatal Rule
About CynapsusLine SeperationAPL-130277 ProductLine SeperationParkinson's DiseaseLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2016, Cynapsus Therapeutics Inc.
All rights reserved.

Traded on